GlassScriptPhysician profile
Sumir M Patel
NPI 1801858113
$4,608.01
in general payments reported to CMS, 2019-2025
35 companies · $812 in 2025
The $812 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $454 · 2020: $244 · 2021: $478 · 2022: $1,010 · 2023: $874 · 2024: $736 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,422.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,611.61 | 2021-2025 | |
| Braintree Laboratories, INC. | $378.84 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $321.92 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $319.70 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $271.06 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $246.26 | 2020-2024 | Trulance, Xifaxan |
| Ipsen Biopharmaceuticals, INC | $183.74 | 2024-2025 | Iqirvo |
| Genentech USA, INC. | $148.75 | 2022 | |
| Organon LLC | $143.79 | 2022-2025 | Renflexis, Nexplanon, Hadlima |
| Celgene Corporation | $139.92 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $101.82 | 2021-2025 | Cimzia, Rebyota |
| Qol Medical, LLC | $96.55 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $71.45 | 2022-2025 | Ibsrela |
| Amgen INC. | $67.95 | 2020-2025 | Avsola, Amjevita |
| Fujifilm Healthcare Americas Corporation | $45.18 | 2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $43.70 | 2023-2024 | Omvoh |
| Lucid Diagnostics INC. | $42.89 | 2021 | |
| Gilead Sciences, INC. | $38.01 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $35.68 | 2019 | |
| Aimmune Therapeutics, INC. | $29.34 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $28.43 | 2022 | |
| Nestle Healthcare Nutrition INC. | $28.21 | 2021 | |
| Phathom Pharmaceuticals, INC. | $27.48 | 2023 | Voquezna |
| Boston Scientific Corporation | $25.66 | 2023 | Watchman Flx |
| Madrigal Pharmaceuticals | $23.88 | 2025 | Rezdiffra |
| Biocon Biologics INC | $20.38 | 2025 | Yesintek |
| Ironwood Pharmaceuticals, INC | $17.12 | 2020 | |
| Redhill Biopharma INC. | $17.08 | 2023 | |
| Alfasigma USA, INC. | $15.59 | 2020 | |
| Intercept Pharmaceuticals, INC. | $15.48 | 2024 | |
| Laborie Medical Technologies Corp. | $14.73 | 2024 | Solar Uroflow System |
| Alnylam Pharmaceuticals INC. | $14.00 | 2023 | Amvuttra |
| Evoke Pharma, INC. | $13.28 | 2024 | |
| Intra-Sana Laboratories | $8.53 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,503.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumir Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.